## HIV Rapid Testing MPEP September 2009 Panel and Vial Designations, CDC Donor Bulk Numbers, CDC HIV Rapid Test Results and Donor HIV Status

Panel Letter	Vial Label	CDC Donor Bulk Number	CDC Test Result <sup>1,3</sup>	Donor HIV Status	Laboratory Interpretation <sup>2</sup> and/or Results	
					Test Result	Interpretation
A	A1	27	Negative (N)	Uninfected		
	A2	13	Positive (S)	Infected		
	A3	23	Positive (W)	Infected		
	A4	13*	Positive (S)	Infected		
	A5	23*	Positive (W)	Infected		
	A6	24	Positive (W)	Infected		
В	B1	13	Positive (S)	Infected		
	B2	27	Negative (N)	Uninfected		
	B3	23	Positive (W)	Infected		
	B4	23*	Positive (W)	Infected		
	B5	24	Positive (W)	Infected		
	В6	13*	Positive (S)	Infected		
С	C1	23	Positive (W)	Infected		
	C2	24	Positive (W)	Infected		
	C3	27	Negative (N)	Uninfected		
	C4	13	Positive (S)	Infected		
	C5	13*	Positive (S)	Infected		
	C6	23*	Positive (W)	Infected		
-	D.1	2.2	D 11 (T:D	T ( )		
D	D1	23	Positive (W)	Infected		
	D2	13	Positive (S)	Infected		
	D3	13*	Positive (S)	Infected		
	D4	27	Negative (N)	Uninfected		
	D5	23*	Positive (W)	Infected		
	D6	24	Positive (W)	Infected		

<sup>\*</sup> Duplicate donors

The CDC result was obtained after pre-shipment testing for the presence of HIV-1 Antibody with all commercially available HIV Rapid Testing kits licensed by the Food and Drug Administration (FDA) and with selected FDA-licensed Enzyme Immunoassay (EIA) kits. The CDC result is consistent with the manufacturers' criteria for interpretation of results.

<sup>&</sup>lt;sup>2</sup> Laboratory Interpretation space (to be completed by participant laboratory) provided to facilitate comparison of participant laboratory result with CDC result.

<sup>&</sup>lt;sup>3</sup> Strong (S) and Weak (W) designations are based on qualitative observations of the colorimetric test results for reactive samples.